Breaking News, Collaborations & Alliances

Maravai Expands CDMO Capabilities Through TriLink Biotechnologies

Offers end-to-end mRNA production with the launch of TriLink's plasmid DNA manufacturing services.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Maravai LifeSciences, a global provider of life science reagents and services to researchers and biotech innovators, has expanded its contract development and manufacturing organization (CDMO) capabilities at TriLink BioTechnologies with the launch of its plasmid DNA (pDNA) manufacturing services. TriLink’s new plasmid services offers customers the ease of an end-to-end messenger RNA (mRNA) solution from a single partner—with Current Good Manufacturing Practice (cGMP) capabilities from plasmid p...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters